Dave Edgren

As Chief Scientist at SinuSys Corp., Dave Edgren leverages his extensive expertise in drug delivery systems to drive innovative solutions in the biomedical engineering landscape. With a strong foundation in formulating osmotic and erodible hydrogel mechanisms, Dave has played a pivotal role in advancing the development of cutting-edge medical devices aimed at enhancing patient outcomes. His leadership in multi-functional project teams has not only fostered collaboration but also built consensus around complex projects, ensuring that diverse perspectives are integrated into the design and development process.

One of Dave's key achievements includes leading the team responsible for the creation of a rate-controlling membrane that became integral to Concerta, a commercially successful oral medication for attention deficit disorder. This experience underscores his proficiency in drug development and highlights his ability to translate scientific research into viable therapeutic solutions. At SinuSys, he has designed and developed osmotic dilators specifically for remodeling biological tissues, showcasing his innovative approach to addressing unmet clinical needs.

Dave's work extends to the identification and formulation of semipermeable elastomeric membrane systems and osmotic engines, which are crucial for dilating biological ducts. His commitment to advancing medical technology is evident in his design and fabrication of prototype devices for dilating nasal ostia, which have demonstrated successful functionality in both animal models and human trials. With a strong background in analytical chemistry and a thorough understanding of Good Laboratory Practice (GLP), Dave Edgren continues to push the boundaries of drug delivery and biomedical engineering, making significant contributions to the pharmaceutical industry and improving the quality of life for patients.